Success Metrics

Clinical Success Rate
89.5%

Based on 17 completed trials

Completion Rate
89%(17/19)
Active Trials
0(0%)
Results Posted
71%(12 trials)
Terminated
2(9%)

Phase Distribution

Ph phase_3
3
13%
Ph phase_4
7
30%
Ph phase_1
3
13%
Ph phase_2
9
39%
Ph not_applicable
1
4%

Phase Distribution

3

Early Stage

9

Mid Stage

10

Late Stage

Phase Distribution23 total trials
Phase 1Safety & dosage
3(13.0%)
Phase 2Efficacy & side effects
9(39.1%)
Phase 3Large-scale testing
3(13.0%)
Phase 4Post-market surveillance
7(30.4%)
N/ANon-phased studies
1(4.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.0%

17 of 21 finished

Non-Completion Rate

19.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

23

all time

Status Distribution
Active(1)
Completed(17)
Terminated(4)
Other(1)

Detailed Status

Completed17
Terminated2
Withdrawn2
Not yet recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
23
Active
0
Success Rate
89.5%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (13.0%)
Phase 29 (39.1%)
Phase 33 (13.0%)
Phase 47 (30.4%)
N/A1 (4.3%)

Trials by Status

terminated29%
not_yet_recruiting14%
completed1774%
withdrawn29%
unknown14%

Recent Activity

Clinical Trials (23)

Showing 20 of 23 trialsScroll for more
NCT07041203Phase 1

Extended-release Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor

Not Yet Recruiting
NCT03292458Phase 2

Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor

Completed
NCT04006925Phase 4

Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate

Completed
NCT01584934Phase 4

Sodium Oxybate in Patients With Chronic Fatigue Syndrome.

Withdrawn
NCT00641186Phase 2

Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD)

Completed
NCT02111122Phase 2

Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease

Completed
NCT04648423Phase 4

Evaluation of the Efficacy of Sodium Oxybate in the Long-term Maintenance of Abstinence in Alcoholic Patients

Completed
NCT02055898Phase 4

SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE)

Completed
NCT02063217Not Applicable

Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction

Completed
NCT00744393Phase 2

The Effect of Sodium Oxybate on Sleep Architecture

Withdrawn
NCT01961297Phase 2

Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response

Completed
NCT00383643Phase 2

Xyrem(Sodium Oxybate) and Ambien(Zolpidem Tartrate) in the Treatment of Chronic Insomnia.

Completed
NCT00498485Phase 4

Use of Xyrem to Improve Sleep in Chronic Fatigue Syndrome

Terminated
NCT00594256Phase 2

Sodium Oxybate in Schizophrenia With Insomnia

Completed
NCT02637648Phase 3

Sodium Oxybate in Patients With Episodic and Chronic Cluster Headache

Unknown
NCT02215499Phase 1

A Phase 1, Single Dose Study of JZP-386 to Evaluate Safety, Pharmacokinetics and Pharmacodynamics

Completed
NCT00931164Phase 1

Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO)

Completed
NCT00598078Phase 2

Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor

Completed
NCT00803023Phase 3

Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia

Completed
NCT00514995Phase 2

Sodium Oxybate in the Treatment of Binge Eating Disorder

Completed

Drug Details

Intervention Type
DRUG
Total Trials
23